Brokers Set Expectations for Selecta Biosciences, Inc.’s Q2 2022 Earnings (NASDAQ:SELB)
Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) – Equities research analysts at SVB Leerink issued their Q2 2022 earnings per share (EPS) estimates for Selecta Biosciences in a report released on Monday, June 6th. SVB Leerink analyst J. Schwartz forecasts that the company will earn ($0.06) per share for the quarter. SVB Leerink has a “Outperform” rating and a $7.00 price target on the stock. SVB Leerink also issued estimates for Selecta Biosciences’ Q3 2022 earnings at ($0.06) EPS, Q4 2022 earnings at ($0.07) EPS, FY2022 earnings at $0.01 EPS, Q1 2023 earnings at ($0.08) EPS, Q2 2023 earnings at ($0.09) EPS, Q3 2023 earnings at ($0.09) EPS, Q4 2023 earnings at $0.05 EPS, FY2023 earnings at ($0.20) EPS, FY2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.23) EPS and FY2026 earnings at ($0.44) EPS. Selecta Biosciences (NASDAQ:SELB – Get Rating) last released its earnings results on Thursday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.19. Selecta Biosciences had a negative return on equity of 33.56% and a net margin of 25.63%. During the same quarter in the previous year, the business posted ($0.22) EPS.
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
A number of other research firms have also issued reports on SELB. StockNews.com lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 14th. TheStreet raised Selecta Biosciences from a “d” rating to a “c-” rating in a report on Wednesday, May 25th. Finally, Zacks Investment Research raised shares of Selecta Biosciences from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Wednesday, May 11th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Selecta Biosciences has a consensus rating of “Buy” and a consensus target price of $5.71.
NASDAQ:SELB opened at $1.17 on Wednesday. The company has a market cap of $177.62 million, a P/E ratio of -23.40 and a beta of 1.35. Selecta Biosciences has a fifty-two week low of $0.65 and a fifty-two week high of $5.28. The company has a quick ratio of 3.31, a current ratio of 3.31 and a debt-to-equity ratio of 0.45. The firm’s 50 day moving average is $0.91 and its two-hundred day moving average is $1.92.
Several hedge funds have recently made changes to their positions in SELB. Mirabella Financial Services LLP bought a new stake in shares of Selecta Biosciences during the first quarter valued at approximately $82,000. Beacon Pointe Advisors LLC bought a new stake in Selecta Biosciences in the 1st quarter valued at $33,000. Endurant Capital Management LP raised its stake in shares of Selecta Biosciences by 62.6% in the 1st quarter. Endurant Capital Management LP now owns 3,451,958 shares of the company’s stock valued at $4,246,000 after buying an additional 1,328,432 shares in the last quarter. Eqis Capital Management Inc. acquired a new position in shares of Selecta Biosciences in the 1st quarter valued at $30,000. Finally, State Street Corp lifted its holdings in shares of Selecta Biosciences by 4.7% during the 1st quarter. State Street Corp now owns 1,790,985 shares of the company’s stock worth $2,203,000 after acquiring an additional 80,662 shares during the period. Institutional investors own 72.62% of the company’s stock.
In related news, Director Timothy C. Barabe acquired 50,000 shares of the stock in a transaction dated Monday, May 9th. The shares were acquired at an average price of $0.77 per share, for a total transaction of $38,500.00. Following the completion of the purchase, the director now owns 250,013 shares in the company, valued at approximately $192,510.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 30.50% of the stock is currently owned by corporate insiders.
Selecta Biosciences Company Profile (Get Rating)
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Selecta Biosciences right now?
Before you consider Selecta Biosciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Selecta Biosciences wasn’t on the list.
While Selecta Biosciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
